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Abstract 
The use of the undecapeptide cyclosporine and the macrolide tacrolimus as immunosuppressants in transplantation 
medicine and for the therapy of immune diseases often provokes side effects, among the most important one is 
neurotoxicity. Changes in the cellular metabolism of glial cells (C6 rat glioma), neuronal cells (N1E-115 mouse 
neuroblastoma) and primary glia cells (isolated from rats) after addition of cyclosporine and tacrolimus were investigated 
using 1H-, 13 C- and 31P-NMR spectroscopy in vitro. Cells were exposed to various concentrations of the drugs from 3 h to 
42 days. The immunosuppressants (cyclosporine IC50:55 ixmol/1; tacrolimus ICs0:47 ixmol/1) inhibited cell proliferation 
in a concentration- and time-dependent fashion. Multinuclear NMR studies of PCA extracts of drug-treated cells showed a 
significant deterioration i the energy status (a decreasing level of PCr: -46  + 11%; an increasing NDP/NTP ratio: 
+ 136 ___ 4% and an increa,;ing level of Pi: +248 + 15%; mean ___ standard eviation). It also showed decreasing concentra- 
tions of major cell metabo]&es like NAA ( -  59 + 12%) in neuroblastoma cells and myo-inositol ( -  47 + 6%) in glia cells 
compared with untreated controls. Immunosuppressive tr atment caused a large reduction of taurine ( -36  ___ 12%) and 
glutamate ( -68  ___ 10%) in all cell cultures, whereas intermediates of phospholipid biosynthesis (PE: +59 ___ 13%; PC: 
+ 127 + 27%;) and breakdown (GPE: +215 + 24%; GPC: +245 ___ 17%) increased. No significant differences were 
observed between the two immunosuppressants. Thetoxic effects of immunosuppressants on cell cultures are in line with 
MRI studies of brain oedema observed in patients under immunosuppressive treatment. 
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Abbreviations: DMEM, Dulbecco's modified Eagle's medium; 
FCS, fetal calf serum; GPC, glycerophosphocholine; GPE, glyc- 
erophosphoethanolamine; IC,;o,half maximal inhibition concen- 
tration; NAA, N-acetyl aspaI~ate; NDP, nucleotide diphosphate; 
NMR, nuclear magnetic resonance; NTP, nucleotide triphosphate; 
Pi, inorganic phosphate; PBS, phosphate-buffered saline; PC, 
phosphorylcholine; PCA, perchloric acid; PCr, phosphocreatine; 
PE, phosphorylethanolamine; TSP, (trimethylsilyl) propionic- 
2,2,3,3-dn-acid. 
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1. Introduction 
Cyclosporine (Sandimmune ~, Sandoz, Basle, 
Switzerland) is a well-established immunosuppres- 
sant in transplantation medicine [1,2] and is used for 
the therapy of autoimmune diseases [3,4]. It is a 
lipophilic undecapeptide consisting of 11 amino acids 
(molecular weight: 1203.6 g/mol) and was isolated 
from the fungus Tolypocadium inflatum Gains [5]. 
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Cyclosporine is considered as a non-cytotoxic drug 
with potent immunosuppressant ctivity on both hu- 
moral and cellular systems, e.g., inhibition of T-cell 
activation cascade [6,7]. The agent was excreted via 
the hepatic cytochrome P450 oxidase system [8]. Its 
therapeutic use is limited by its side effects among 
which nephrotoxicity, hepatoxicity, induction of dia- 
betes, induction of hypertension a d neurotoxicity are 
most notorious [9-13]. 
Tacrolimus (FK506, Prograf ®, Fujsawa, Osaka, 
Japan) is mainly applied as an immunosuppressant 
after liver transplantation a d for graft rescue therapy 
[14,15] and has meanwhile been approved in several 
countries. Its macrolide lactone structure (803.5 
g/mol) comprises a 23-member carbon ring and a 
hemiketal-masked o~, [3-diketoamide function and was 
isolated from the fungus Streptomyces t ukubaensis 
[16]. The complex of tacrolimus and its intracellular 
binding protein FKBP is assumed to suppress T- 
lymphocyte activation at an early stage (G0-G 1 phase), 
resulting in an inhibition of transcription of lym- 
phokines (particularly interleukin-2), a process that 
involves an increase in intracellular [Ca 2+ ] levels 
[17]. The major side-effects are identical with those 
of cyclosporine [14,15,17]. 
The most important neurotoxic effects of immuno- 
suppressive therapy are tremor, depression, cortical 
blindness, cerebral dysfunction, seizures, paraesthesia 
and encephalopathy [18-20]. While the mechanisms 
underlying immunosuppressive activity [21,22] are 
well known, only little is known about he biochemi- 
cal mechanisms responsible for neurotoxicity. While 
well-defined models exist for the assessment of im- 
munosuppressive activity [23], this is not the case for 
toxicity which requires screening of the total cell 
metabolism. 
Cell culture systems represent a very useful method 
for observing pathological changes under immuno- 
suppressive stress [24]. Previous studies [25] have 
demonstrated specific inhibition of DNA, RNA and 
protein synthesis in animal renal and non-renal cell 
lines by cyclosporine. Drug-treated rat microvascular 
endothelial cells have revealed abnormal morphologi- 
cal changes, such as formation of cytoplasmatic vesi- 
cles and nucleolar changes, and also inhibition of 
prostacycline synthesis [26]. In cultured human epi- 
dermal keratinocytes, cyclosporine demonstrated an
antiproliferative effect in an early phase (G0/G 0 of 
the cell cycle [27]. Nevertheless, these studies pro- 
vided little information about changes in the cellular 
metabolism and the energy state associated with the 
toxicity of immunosuppressive drugs. 
Multinuclear NMR spectroscopy of cell lines or 
primary cultures, is a potent technique to evaluate 
and characterize toxicity mechanisms in vitro [28,29]. 
We used its to assess changes of major metabolites in
cell extracts from clonal cell lines of neuronal and 
glial origin and in primary glia cells under immuno- 
suppressive stress. Proton NMR spectra of PCA ex- 
tracts were used to characterize the changes of sev- 
eral amino acids and other water-soluble metabolites. 
The energy status of the cells was characterized by 
31p-NMR spectroscopy. 13C-NMR spectroscopy was 
used to follow up the cellular metabolism in the 
steady-state of the cells. 
2. Materials and methods 
2.1. Materials 
Mouse neuroblastoma C1300, subclone N1E-115 
[30], originated in the laboratory of M. Nirenberg, 
was obtained from E. Yavin (Weizmann Institute, 
Israel). Rat C6 glioma cells [31] were purchased from 
ICN Biomedicals (Meckenheim, Germany). The ani- 
mals used for primary cell preparation were Wistar 
rats of random sex. Pregnant female rats were sup- 
plied by Charles River Ltd. (Sulzfeld, Germany). 
Cyclosporine was a kind gift from Sandoz (Niire- 
nberg, Germany) and tacrolimus a gift from Fujisawa 
(Munich, Germany). 
DMEM, FCS and penicillin/streptomycin, PBS 
and trypsin/EDTA were purchased from Gibco 
(Eggenstein, Germany). Tissue culture flasks, culture 
Petri dishes and multi-well plates flat base were 
obtained from Nunc (Wiesbaden, Germany). 
[1-13C]Glucose was purchased from Cambridge 
Isotope Laboratories (Promochem, Wesel, Germany), 
TSP from Aldrich (Steinheim, Germany). Deuterated 
solvents as well as EDTA were obtained from E. 
Merck (Darmstadt, Germany). 
2.2. Cell cultures 
All cell types described were adherently growing 
cells. The cultures were incubated at 37°C in 90/10% 
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atmospheric air/CO 2 (vol/vol) in DMEM and were 
grown to confluency in 10- or 15-cm Petri dishes. 
DMEM was supplemented with penicillin/strepto- 
mycin (100 units/ml medium) and FCS: N1E-115 
neuroblastoma and prim~a'y glia cells with 10% FCS, 
and C6 glioma cells with 5% FCS. After reduction of 
FCS from 10% to 0.6%. by half dilution with pure 
DMEM in five steps over six days, N1E-115 cells 
differentiated to neuronal cells [30,32]. 
Cultures of primary glia cells were prepared from 
three brains of 1- to 4-day-old newborn rats. The 
cerebral hemispheres were carefully dissected from 
the brains, the meninges were cut and the cerebral 
tissue was mechanically disrupted. The resulting cell 
suspensions were plated on 260 ml-culture flasks 
(one brain/flask) and DMEM containing 10% FCS 
was added. After 10 day,; of preculture, the cells were 
removed from the culture flasks by mild trypsiniza- 
tion (50 mg trypsin and 20 mg EDTA/1) and replated 
on 15 cm-culture Petri d]ishes (three Petri dishes from 
one flask). Thereafter, the primary glia cells were 
cultured for another 24 days. The growth medium 
was routinely changed twice per a week. The age of 
the culture is given as the total time after preparation 
of the cells (34 days). 
2.3. Treatment with drugs 
Stock solutions at 1 g/1 were prepared for cy- 
closporine (in 50/50 vol/vol acetonitrile/sulfuric 
acid, pH 3) and tacrolirnus (in 70/30 vol/vol aceto- 
nitrile/sulfuric acid, pHI 3) and kept at +4°C. The 
stock solutions, as checked by HPLC, proved to be 
stable for at least 4 weeks. Dilutions were freshly 
prepared using DMEM. The concentration of aceto- 
nitrile in the cultures was always less than 1.4% for 
short-term incubation (3 h) and less than 0.4% for 
long-term incubation (42 days). Drug-free medium 
solutions with up to 3% acetonitrile caused no NMR 
detectable effects on the cell metabolism. 
Cells were treated with different drug concentra- 
tions for various periods of time. The highest concen- 
trations (20 mg/1 for glioma and neuroblastoma cells; 
10 mg/1 for primary glia cells because of their higher 
sensitivity to the drugs) were added to the short-term 
studies (3 h). For long-term studies (18-24 h) the 
drug concentration added to the clonal cell lines was 
reduced to 10 mg/1. Additionally, neuroblastoma and 
glioma cells were subcultured with drug-containing 
medium (1 and 5 mg/1, three passages) for a total 
culture time of 42 days. After the treatments, the cells 
were extracted with perchloric acid. 
2.4. Perchloric acid extracts 
Cells were included in the study as soon as they 
were confluently growing (approx. 108 cells/dish). 
The cells were washed with PBS and incubated with 
fresh serum-free medium containing 5 mmol/1 [1- 
13C]glucose for 3 h with or without drug. After 
removal of the medium, each culture was washed 
twice with 4 ml ice-cold NaC1 solution (0.9%) per 
dish and all metabolic activity was immediately 
stopped by freezing in liquid nitrogen. The thawed 
cells were extracted twice with 2 ml ice-cold PCA 
(12%) and centrifuged (1500 X g, 10 rain). The aque- 
ous phase was removed, neutralized using KOH and 
lyophilized. 
2.5. Protein determination 
After centrifugation and removal of the super- 
natant, the material remaining in the centrifuge tube 
was redissolved using 3 ml water. The protein con- 
centration was quantified using a modified Biuret 
reaction described by Goa [33]. To 50, 100 and 150 
ml of the resuspended material water was added to 
result in a final volume of 500 ml. Five hundred ml 
6% NaOH and 250 ml Biuret reagent solution were 
added and the UV absorption was recorded at 540 nm 
after incubating for 30 min at room temperature. The 
protein concentrations were calculated using an exter- 
nal standard curve based on bovine serum. 
2.6. NMR spectroscopy 
The lyophilized PCA extracts were redissolved in 
450 ml D20 and pH 7 was adjusted using DC1 and 
1 13 31 KOD before recording H-, C- and P-NMR spec- 
tra. TSP was used as an external standard for quan- 
tification. Spectra are recorded on a AM360 spec- 
trometer (Bruker, Karlsruhe, Germany) and processed 
using the DISNMR 91 program (Bruker, Karlsruhe, 
Germany). Quantitation is made in correlation with 
the protein contents obtained by the Biuret reaction. 
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2.6.1. 1H-NMR 
The operating frequency was 360 MHz. A 5 mm- 
~H probe was used. The other parameters were: 200 
accumulations; flip angle: 40°; repetition time: 12 s; 
spectral width: 3600 Hz; data size: 16 K; zero filling 
to 32 K. Chemical shifts were referenced to TSP at 0 
ppm. 
2.6.2. 13C-NMR 
The 13C-NMR spectra were subsequently recorded 
from the same solutions as the 1H-NMR spectra. A 5 
mm-1H/13C dual probe was used. The NMR param- 
eters were: operating frequency of 90.5 MHz; 20 000 
accumulations; flip angle: 27°; repetition time: 2.5 s; 
spectral width: 17860 Hz; data size: 16 K; and zero 
filling: 32 K. Composite pulse decoupling (CPD) was 
used. The C1 of [3-glucose was used as chemical 
shift reference at 96.8 ppm. 
2.6.3. 31p-NMR 
Before the 31p-NMR spectra were recorded, 100 
mmol/1 EDTA was added for complexation of diva- 
lent ions. This resulted in 31p-NMR spectra with a 
significantly narrower line width. The pH was ad- 
justed to 7 using KOH and HC1. The following NMR 
parameters were used: operating frequency: 145.7 
MHz; 10 mm-lH/31p dual probe; 5000 accumula- 
tions; flip angle: 80°; repetition time: 3.5 s; spectral 
width: 5000 Hz; data size: 8 K; zero filling to 16 K. 
Composite pulse decoupling (CPD) was used. Either 
phosphocreatine (PCr) at -2 .33  ppm, if present, or 
o~-NTP at -9 .90  ppm were used as shift references. 
2.7. DNA quantification 
N1E-115 neuroblastoma cells (5 × 108 cells/well) 
were plated in 24-well plates and incubated for 48 h 
(see above). Then the cells were washed with 1 ml 
phosphate-buffered saline/well and subsequently in- 
cubated with fresh medium containing tacrolimus at 
concentrations from 0 to 55 mg/1 (0-68 ixmol/1) 
and cyclosporine at concentrations from 0 to 80 mg/1 
(0-66 p~mol/1) for 3 h or 24 h. After incubation, the 
medium was removed. The cells were washed with 1 
ml ice-cold PBS. The DNA concentration was quanti- 
fied using a modification of the method described by 
Burton [34]. The cells were scraped with 300 ml 
water and 700 ml of the reagent containing 10 mg/1 
acetaldehyde were added. After a reaction time of 20 
h, the UV-absorption was recorded at 600 nm. The 
DNA was quantified using an external standard curve 
based upon herring sperm. 
2.8. Statistical analysis 
The results are given as means_  standard devia- 
tion (S.D.) for each series of experiments. The results 
of the controls and of cells incubated with cy- 
closporine or tacrolimus were compared using analy- 
sis of variance in combination with Duncan grouping 
(procedure GLM, SAS statistic package, SAS Insti- 
tute, Cary, NC). 
3. Results 
3.1. DNA concentration 
Addition of the immunosuppressants tacrolimus 
and cyclosporine led to a time- and concentration-de- 
pendent decrease of the DNA content of a N1E-115 
neuroblastoma cell culture. The DNA concentration 
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100 ~ 3hwithFK506 
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Fig. 1. Effect of cyclosporine and tacrolimus on the DNA 
concentration in N1E-115 neuroblastoma cells for 3 h. The DNA 
concentrations of the drug-treated cells are compared with the 
DNA concentrations of the untreated controls (100%). All data 
for the high concentrations of cyclosporine (10-80 mg/1) are 
significantly different from control (P < 0.02). All data for the 
high concentrations of tacrolimus (5-55 mg/l) are significantly 
different from control (P < 0.01). The data for the lowest dose of 
cyclosporine (2and 5 rag/l) and of tacrolimus (2 mg/1) are not 
significantly different. 
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in the control cultures was 16.7 +3.5 mg/wel l  
(mean + standard eviation, n = 5). The DNA con- 
centration was 15% lower than the controls when 10 
mg/1 cyclosporine and 65% lower when 80 mg/1 
were added for 3 h (P < 0.02) (Fig. 1). The DNA 
concentration decreased by 10% compared with the 
controls when 2 mg/ l  tacrolimus and by 85% when 
55 mg/1 were added (P < 0.02) (Fig. 1). The DNA 
concentration per multiwell was especially reduced 
by tacrolimus: the effect ICs0s for cyclosporine and 
tacrolimus were 66 rag/1 (55 lxmol/1) and 38 rag/1 
(47 ixmol/1), respectively. An even larger decrease 
of the DNA concentration per multiwell compared 
with 3-h incubations was evident after incubating for 
24 h (cyclosporine: IC50 = 12 Ixmol/1; tacrolimus: 7
Ixmol/1). For the NMR experiments, the cells were 
treated with drug concentrations leading to a 30% 
decrease in the DNA content per rnultiwell compared 
with control experiments. 
3.2. Energy status 
Fig. 2 compares representative 31p-NMR spectra 
of PCA extracts of primary glia cells after 3 h 
incubation with (Fig. 2A) and without (Fig. 2B) 
cyclosporine. The intensity of the phosphocreatine 
signal (PCr; -2.33 ppm) in the drug-treated cells 
was reduced to as much as 46% of that detected in 
A 
PI 
GPE 
GPC 
PCr 
NTP 
. . . .  . . . .  . . . .  - i s  . . . .  
ppra 
Fig. 2. 31p_NMR spectra of PCA extracts from primary glia cells: (A) incubation with 10 mg/1 cyclosporine for 3 h; (B) control. 
Abbreviations: glycerophosphocholine (GPC), glycerophosphoethanolamine (GPE), nucleotide iphosphate (NDP), nucleotide triphos- 
phate (NTP), inorganic phosphate (Pi), phosphocreatine (PCr), phosphorylcholine (PC), phosphorylethanolamine (PE). 
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Table 1 
Changes of the 
the presence of 
metabolite concentrations in primary glia cells in 
immunosuppressants for 3 h 
Control nmol Cs A, 10 mg FK506, 4 mg 
/mg /1% /1% 
protein 
Val, Ile, Leu 29.6_+ 1.1 86_+ 10 * 103_+7 
Lactate 33.7 _+ 6.3 96 ± 11 109 _+ 4 * 
Glutamine 53.1 _+5.3 64_+5 * * 88_+ 12 * 
Taurine 61.6_+7.1 64_+ 12 * * 73_+7 * * 
Hypotaurine 69.6_+ 11.3 61 ± 10 * * 80+ 10 * * 
myo-Inositol 44.2_+ 3.9 53 _+ 6 * * * 71 _+ 9 * * 
Creatine 14.7 _+ 4.2 97 _+ 4 97 _+ 5 
PCr 24.6 _+ 7.6 83 _+ 1 * * 95 _+ 2 * 
PE 21.6_+4.4 118_+7 * 120_+6 * 
PC 6.8_+2.4 198_+ 18 * * * 160_+ 12 * * * 
GPE 5.4_+ 1.2 137_+ 17 * * 120_+7 * * 
GPC 25.2_+5.5 127_+11 ** 133_+14 ** 
The values are means_+ standard eviations; % = percent of con- 
trol. * Significantly different from control (P  < 0.05, n = 3); 
* * P < 0.02; * * * P < 0.01 (ANOVA test). Abbreviations: cy- 
closporine (Cs A), glycerophosphocholine (GPC), glycerophos- 
phoethanolamine (GPE), isoleucine (Ile), leucine (Leu), phospho- 
creatine (PCr), phosphorylcholine (PC), phosphorylethanolamine 
(PE), tacrolimus (FK506), valine (Val). 
the  cont ro l s  (Tab les  ! and  2). The  phosphocreat ine  
concent ra t ion  in pr imary  g l ia  and  C6  g l ioma ce l l s  
was  reduced espec ia l l y  by  cyc lospor ine .  N1E-115 
neurob las toma ce l ls  conta in  no  NMR-detectab le  con-  
cent ra t ion  o f  phosphocreat ine  [35]. A s ign i f i cant  de-  
c rease  o f  the  phosphocreat ine  concent ra t ion  was  a lso  
detectab le  in the  1H-NMR spect ra  o f  PCA ext racts  
f rom g l ia  ce l l s  (Tab les  1 and  2). The  ra t io  o f  the  CH 3 
s ing le t  o f  c reat ine ,  and  the cor respond ing  s ing le t  o f  
phosphocreat ine  at 3.05,  was  reversed  when cy-  
c lospor ine  was  added (w i thout  cyc lospor ine :  0.8;  w i th  
cyc lospor ine :  1.3). Fur thermore ,  in compar i son  w i th  
the cont ro l s ,  al l  31p-NMR spect ra  showed an  in-  
c reased  rat io  o f  nuc leot ide  d iphosphates /nuc leot ide  
t r iphosphates  (P  < 0 .05)  a f ter  add i t ion  o f  immuno-  
suppressants  for  3 h (Tab le  4). T reatment  w i th  im-  
munosuppressants  caused  the increas ing  leve l  o f  inor -  
gan ic  phosphate  (P~: +248 _+ 15% o f  cont ro l )  in al l  
ce l l  types  (F ig,  2). 
3.3. Steady-state concentration of various metabolites 
The e f fec ts  o f  immunosuppressants  on  the  
metabo l i sm o f  the  d i f fe rent  ce l l  types  inc luded in the  
Table 2 
Changes of the metabolite concentrations in C6 glioma cells in the presence of immunosnppressants 
Control Cs A, Cs A, Cs A, FK506, FK506, FK506, 
(nM/mg 20 rag/ l ,  10 rag/ l ,  5 mg/1, 20 mg/1, 10 rag/ l ,  5 mg/1, 
protein) 3 h (%) 18 h (%) 40 d. (%) 3 h (%) 18 h (%) 39 d. (%) 
Val, Ile, Leu 22.5_+2.1 103+6 97-+5 89_+10 114_+9 * 91_+18 97_+4 
Lactate 52.8 -+ 3.1 135 -+ 11 * * 107 _+ 7 105 _+ 12 127 _+ 14 * 125 _+ 7 * * 104 _+ 19 
Alanine 10.2_+1.8 85_+9 * 61±4 *** 57_+7 *** 49_+11 *** 47_+ 14 ** 33+_5 *** 
Glutamate 47.3_+3.5 57_+7 *** 47±9 *** 32_+ 10 *** 71_+7 ** 52±9 *** 41_+ 12 *** 
Glutamine 49.1_+2.9 86_+9 * 53±11 ** 45_+9 *** 82_+8 * 87+6 * 78_+5 ** 
Taurine 13.1+_2.4 79_+10 ** 71_+ 12 ** 78_+5 ** 83_+9 * 71_+8 ** 84_+ 10 ** 
Glycine 31.5_+1.7 89_+8 * 42___14 *** 47_+11 *** 96+7 85_+11 * 67_+8 *** 
myo-Inositol 35.1 -+ 2.8 87 -+ 5 * 84 _+ 4 * * 78 _+ 7 * * 87 _+ 4 * 79 _+ 5 * * 85 _+ 9 
Creatine 5.7 _+ 1.1 91 _+ 2 * 63 ± 15 * * 81 _+ 12 * 102 _+ 15 107 _+ 11 96_+ 14 
PCr 7.3-+0.8 79_+8 ** 67_+ 10 ** 54_+ 11 ** 68_+8 ** 69_+9 ** 62_+ 11 ** 
PE 4.3_+1.1 145_+12 *** 114_+9 * 117_+6 ** 104_+12 134_+17 ** 121±15 ** 
PC 6.4_+1.0 162_+21 *** 132+8 ** 131_+25 ** 154_+19 ** 145_+19 *** 179_+10 *** 
GPE 2.7_+0.5 201_+17 *** 189_+25 *** 171_+ 16 *** 116_+9 * 129_+ 15 ** 188+29 *** 
GPC 5.4_+0.7 274_+32 *** 218±21 *** 259_+ 14 *** 199_+22 *** 187_+24 *** 201_+ 19 *** 
The values are means _+ standard eviations; % = percent of control. * Significantly different from control (P  < 0.05, n = 3); * * P < 
0.02; * * * P < 0.01 (ANOVA test). Abbreviations: cyclosporine (Cs A), glycerophospho-choline (GPC), glycerophosphoethanolamine 
(GPE), isoleucine (Ile), leucine (Leu), phosphocreatine (PCr), phosphorylcholine (PC), phosphorytethanolamine (PC), tacrolimus 
(FK506), valine (Val). 
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present study are listed in Tables 1-3. The most 
pronounced ifferences compared with the controls 
were found for myo-inositol, taurine, glutamate (be- 
low NMR detectability in primary glia cells), glu- 
tamine and alanine. 
The 0.5-4.6 ppm regions of the 1H-NMR spectra 
of PCA extracts (Fig. 3) contained the proton signals 
of various metabolites such as lactate, creatine, phos- 
phocreatine, choline derivatives and several amino 
acids. After a 3-h incubation of the clonal cells with 
the immunosuppressants, the glutamate (Glu; 2.35 
ppm) concentration was 70% of that of the control 
(P<0.02)  and dropped to 28% (P<0.001) after 
exposition to the immunosuppressants for 40 days. 
The signal intensity of glutamine (Gin; 2.44 ppm) 
was significantly lower in the cells incubated with 
immunosuppressants than in those without (P < 
0.05). The 1H-NMR spectra of extracts from neurob- 
lastoma cells (Fig. 3) revealed a reduction of the 
N-acetyl singlet of N-acetyl aspartate (NAA; 2.02 
ppm) by 50% (Table 3). NAA is a neuronal marker 
and therefore not present in the extracts of glioma 
cells. In contrast, myo-inositol (Ins), which is a NMR 
marker for glia cells [36], was only detectable in the 
glioma cells and primary glia and was reduced by 
60% when immunosuppressants were added to the 
cell cultures. Cyclosporine and tacrolimus caused a 
significant decrease (40%) of the osmolyte taurine 
(Tau) in all cell types included in the study (Tables 
1-3). Hypotaurine (HTau) is a characteristic metabo- 
lite in primary glia ceils. Two triplet signals of HTau 
were detected in the 1H-NMR spectra of PCA ex- 
tracts from glia cultures. Addition of cyclosporine for 
3 h decreased the hypotaurine concentration by 40% 
(P < 0.01). 
3.4. Cell metabolism 
~3C-NMR spectroscopy allowed us to follow-up 
the cellular metabolism even in the metabolic 
steady-state of the cells. ~3C-NMR spectra of C6 
glioma cell extracts are shown in Fig. 4. These 
spectra were acquired after a 3-h incubation with 5 
mmol/l  [1-13C]glucose with (Fig. 4A) or without 
(Fig. 4B) tacrolimus. In this experimental set-up, it 
was possible to follow the metabolic pathways of 
glucose, in particular the synthesis of intermediates of 
glycolysis and the tricarboxylic acid (TCA) cycle. In 
the range of 15-65 ppm, several labelled resonances 
which correspond to the major follow-up metabolites 
of the TCA cycle could be detected: glutamate (C2: 
55.8 ppm; C3:28.3 ppm; C4:34.2 ppm), glutamine 
Table 3 
Changes of the metabolite concentrations in N I E-115 neuroblastoma cells in the presence of  immunosuppressants  
Control Cs A, Cs A, Cs A, FK506, FK506, FK506, 
(nM/mg 20 rag / l ,  10 rag / l ,  2 rag / l ,  15 rag / l ,  10 rag / l ,  2 mg/1 ,  
protein) 3 h (%) 21 h (%) 42 d. (%) 3 h (%) 21 h (%) 41 d. (%) 
Val, Ile, Leu 27 .7+1.2  88+13 99+10 108+11 97+4 103+9 89+12 
Lactate 52.8_+3.1 95_+8 125+_12 * 112_+7 * 115_+9 * 95_+7 ** 101 +- 10 
Alanine 16.5_+1.5 58_+3 ***  56_+7 ***  45_+5 ***  70_+8 ** 73+-9  ** 61_+18 ** 
Glutamate 42.1__1.8 67+4 ***  64_+6 ** ~ 52_+9 ***  73+7 ** 56-+11 ***  54-+5 ***  
Glutamine 49.3+_1,9 79_+3 ** 69_+12 ** 56_+9 ***  80-+2 ** 61_+10 ** 68_+8 ** 
Aspartate 28.6_+1.2 454-12  ***  55_+11 ***  67_+4 ***  62_+11 ** 62_+8 ** 47+7 ***  
NAA 11.5_+1,6 52_+17 ** 57_+11 ***  52_+13 ***  67_+15 ** 64_+17 * 41_+12 ***  
Taurine 11.3_+2.3 77_+7 * 78_+9 ** 65+_11 ** 82_+7 * 70_+9 ** 69_+4 ***  
Glycine 52.2_+2.6 78_+4 ** 62_+10 ** 64_+10 ** 76_+3 ** 62_+9 ** 61_+11 ** 
PE 48.1_+2.1 119_+ 12 * 134-+15 ** 138_+11 ** 141-+17 ** 159_+13 ** 140_+21 ** 
PC 7.1 -+1.9 128-+4 ***  131-+14 ** 197-+18 ***  155-+23 ** 227_+27 ***  200-+11 ***  
GPE 2.8_+0.5 144_+21 ** 129_+11 ** 145_+19 ** 201-+12 ***  315+_24 ***  247_+26 ***  
GPC 6.9_+2.0 161+-31 ***  201_+ 17 ***  231_+17 ***  289+19 ***  345_+17 ***  301_+18 ***  
The values are means  + s;tandard deviations; % = percent of  control. * Significantly different f rom control (P  < 0.05, n = 3); 
• * P < 0.02; * * * P < 0.01 (ANOVA test). Abbreviations: cyclosporine (Cs A), glycerophosphochol ine (GPC), glycerophospho- 
ethanolamine (GPE), isoleucine (lie), leucine (Leu), N-acetyl aspartate (NAA),  phosphorylchol ine (PC), phosphorylethanolamine (PE), 
tacrol imus (FK506), valine (Val). 
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(C2:55.4 ppm; C3:27.5 ppm; C4:32.0 ppm), aspar- 
tate (C2:53.4 ppm; C3:37.8 ppm) and proline (C4: 
23.2 ppm) (Fig. 4). The following products of glycol- 
ysis could be determined: lactate (C3:21.2 ppm), 
alanine (C3:17.3 ppm), serine (C3:61.4 ppm) and 
glycine (C2:42.7 ppm). The spectra of PCA extracts 
from glia cells also showed in the low field region 
(70-75 ppm) the signals of myo-inositol in natural 
abundance of its 13C-carbons (Fig. 4). The 13C-NMR 
spectra of extracts from primary glia cells contained 
signals of taurine (CI: 48.4 ppm; C2:36.2 ppm) and 
hypotaurine (CI: 56.8 ppm; C2:34.6 ppm) (data not 
shown). The reduced 13C intensities of myo-inositol, 
taurine and hypotaurine correspond well to the de- 
creased concentrations of these metabolites after the 
addition of immunosuppressants demonstrated by ~ H- 
NMR spectroscopy. The addition of immunosuppres- 
sants caused a reduction of about 40% of the 13C- 
labels of alanine (P < 0.02), glutamate (P < 0.01), 
glutamine (P < 0.02) and aspartate (P < 0.05) com- 
pared with the controls. Within 3 h incubation of 
N1E-115 neuroblastoma cell cultures with immuno- 
suppressants, the ratio of TCA cycle products/gly- 
colysis products decreased to 0.71 ___ 0.07 (mean___ 
standard eviation) compared with 1.54 ___ 0.11 (mean 
___ standard eviation) in control cells (P< 0.001). 
A 
Cho, 
Gly 
B Glx 
I Glu ,, NAA II Gin A1 Leu 
~ ~ T a u  Val 
4.5 4.0 3.5 3.0 2.5 2.0 t .5  t.O 
PPM 
Fig. 3. ]H-NMR spectra of PCA extracts from N1E-115 neuroblastoma cells: (A) treatment with 10 mg/1 tacrolimus for 21 h; (B) 
untreated control cells. Abbreviations: alanine (Ala), aspartate (Asp), choline (Cho), glycerophosphocholine (GPC), glycine (Gly), 
glutamate (Glu), glutamine (Gin), glutamate and glutamine (Glx), lactate (Lac), leucine (Leu), N-acetyl aspartate (NAA), phosphoryl- 
choline (PC), taurine (Tau), valine (Val). 
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The alteration of this ratio with and without immuno- 
suppressants was 1.11 _ 0.10 (mean + standard evi- 
ation) vs. 2.74 _ 0.17 (P < 0.001) and 0.75 +_ 0.14 
vs. 1.27_ 0.19 (P < 0.02) for C6 glioma and pri- 
mary glia cells, respectively. The ratios are obtained 
from the total signal intensity of all NMR detectable 
products of the TCA cycle versus those of glycolysis. 
It is an indicator of shifts towards more anaerobic 
metabolism. 
ethanolamine (PE; 4.8 ppm), phosphorylcholine (PC; 
4.0 ppm), glycerophosphoethanolamine (GPE; 1.1 
ppm) and glycerophosphocholine (GPC; 0.6 ppm). 
Although the basic concentrations of phosphomo- 
noesters and phosphodiesters were considerably ower 
in the tumor cells than in primary cells, in the present 
study there was a significant increase of phospho- 
mono- and diesters in all cell types after incubation 
with immunosuppressants (Tables 1-3). 
3.5. Membrane phospholipid biosynthesis 
The addition of immunosuppressive drugs led to a 
significant increase of anabolic as well as catabolic 
intermediates of membrane phospholipid biosynthe- 
sis. The 3]p-NMR spectra of PCA extracts from 
primary glia cells (Fig. 2) showed several well char- 
acterized signals of the.se metabolites: phosphoryl- 
4. Discussion 
Multinuclear NMR spectroscopy was used to as- 
sess the toxic effects of the immunosuppressants 
cyclosporine and tacrolimus on the metabolism of 
glial and neuronal cell lines and primary glia cells in 
vitro. The effects of the immunosuppressants o  each 
A 
it .,. ,--~_It~:_.~..: "-,~"---.,,-',Z-, 
B 
Glu 
CA 
Glu 
I 
I I IG1. 
C3 C,2 Gly Asp Pro 
¢% 22 .... ~ C3 C4 
L a c  
C3 
A]a 
Q 
. . . .  " . . . .  I . . . .  " . . . .  I . . . .  • . . . .  ! . . . .  " . . . .  I . . . .  " . . . . . . . .  " . . . . . . . .  ° . . . . . . . .  ' . . . .  
70 eo 50 i'o 
PPM 
Fig. 4. 13C-NMR spectra of PCA extracts from C6 glioma cells after a 3-h incubation with 5 mmol/1 [1-13C]glucose (A) with and (B) 
without 5 mg/l  tacrolimus (after a 39-day incubation with 5 mg/l  tacrolimus). Abbreviations: alanine (Ala), aspartate (Asp), glutamate 
(Glu), glutamine (Gln), lactate (Lac), myo-inositol (Ins), proline (Pro), serine (Ser). 
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Table 4 
Ratio of nucleotide diphosphates/nucleotide triphosphates in 
control and after addition of immunosuppressants (3 h) calculated 
from 3J P-NMR spectra of PCA extracts 
NDP/NTP NDP/NTP NDP/NTP 
(Control) (Cs A) (FK506) 
NIE-115 0.21_+0.04 0.26+0.03 ~ 0.29+0.04 * 
neuroblastoma cells 
C6gliomacells 0.15+0.05 0.27+0.07 ~ 0.22_+0.05 * 
primary glia cells 0.31_+0.01 0.34_+0.02 ** 0.42_+0.03 * 
The values are means _+ standard eviations. * Significantly 
different from control (P < 0.05, n = 3); * * P < 0.02 (ANOVA 
test). Abbreviations: nucleotide diphosphate (NDP), nucleotide 
triphosphate (NTP). 
of the three cell types was similar. The concentrations 
of high energy phosphates, organic osmolytes and 
amino acid metabolites were reduced and the concen- 
trations of precursors and catabolic products of mem- 
brane phospholipids were significantly increased (Ta- 
bles 1-3). All these toxic effects proved to be time- 
and concentration-dependent which corresponds well 
to the results of clinical observations and studies 
[9,37,38]. All side effects in patients with cy- 
closporine-induced encephalopathy were reversed 
when the cyclosporine dose was reduced [11,13]. 
Cell viability at the time of extraction was re- 
flected by the energy status represented by the high 
energy phosphates, such as phosphocreatine, nu- 
cleotide diphosphate and nucleotide triphosphate, and 
determined using 31p-NMR spectroscopy. The results 
of the present study showed that addition of immuno- 
suppressants to the cells led to a significant decline of 
their energy status derived from the increasing ratio 
of nucleotide diphosphate/nucleotide triphosphate. 
(Table 4). Our results also showed that the phospho- 
creatine level in the glia cells after immunosuppres- 
sive stress was significantly decreased. The increase 
of the inorganic phosphate is usually consistent with 
a decrease of the high energy phosphates metabolites, 
such as phosphocreatine and nucleotide triphosphate. 
A decrease of phosphocreatine and an increase of the 
NDP/NTP ratio indicate a pathological decline of 
the energy status in the drug-treated cells, while 
untreated control cell cultures preserved their ener- 
getic states in the same period. 
In addition to the reduction of concentrations sev- 
eral intracellular amino acids, especially glutamate 
and glutamine which are neurotransmitters and os- 
moregulators in the brain, concentrations of N-acetyl 
aspartate, a specific marker for neuronal cells [39] 
and concentrations of myo-inositol, a specific marker 
of glia cells [35], were significantly reduced after the 
addition of immunosuppressants. A decrease of N- 
acetyl aspartate in clinical spectroscopy is associated 
with severe neuronal dysfunction or loss [40,41]. The 
N-acetyl aspartate signal in our spectra of the N1E- 
115 cell extracts was much smaller (typical for em- 
bryonal neurons) compared to proton spectra in vivo, 
but the pathological decline of NAA (to 50%) was 
obvious from the spectra of drug-treated neuroblas- 
toma ceils (Table 2). Myo-inositol acts as an organic 
osmolyte and plays a major role in the volume and 
osmotic regulation of glia cells [42]. 
Furthermore, the concentrations of taurine and of 
hypotaurine were reduced by the addition of cy- 
closporine and tacrolimus. Although the role of hy- 
potaurine, an intermediate of taurine synthesis, in glia 
cells is not completely defined, it has been hypothe- 
sized that it acts as a free radical scavenger in a 
putative control mechanism to protect neuronal mem- 
branes from oxidation [43]. Taurine, another metabo- 
lite, is well known as an important osmolyte in the 
brain [44]. 
In addition, 31p-NMR analyses of all PCA extracts 
showed that immunosuppressants al ered the concen- 
trations of the precursors and catabolic products of 
membrane phospholipids such as phosphomonoesters 
and phosphodiesters. The phosphodiester pattern 
showed a shift towards higher concentrations of glyc- 
erophosphoethanolamine and glycerophosphocholine, 
the phosphomonoester pattern towards increased con- 
centrations of phosphorylethanolamine and phos- 
phorylcholine. Increased concentrations of phospho- 
monoesters go parallel with increased biosynthesis of 
cellular membranes and myelin while increased con- 
centrations of phosphodiesters go parallel with in- 
creased egradation. These observations may explain 
the findings in CT and magnetic resonance studies 
[18,38], which indicate a severe, diffuse disorder of 
the white matter after cyclosporine therapy for im- 
munosuppression in liver transplantation. 
Incubation of cell cultures with [1-13C]-labelled 
glucose for 3 h induced characteristic changes of 
several metabolites, synthesized via glycolysis and 
the tricarboxylic acid (TCA) cycle [45]. One of the 
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prominent differences between cells cultivated with 
immunosuppressants and those without was the de- 
crease of all tricarboxylic acid cycles intermediates, 
especially of glutamate, glutamine and aspartate. 
It is concluded that in vitro neurotoxicity of cy- 
closporine and tacrolimus is characterized by inhibi- 
tion of the tricarboxylic acid cycle, reduction of the 
energy status and interference with cell membrane 
synthesis. One of the consequences is a reduction of 
the concentrations of osmolytic amino acids which 
results in swelling of the cells cultivated with im- 
munosuppressants. The toxic effects of immunosup- 
pressants established in the present study may explain 
the result of several in vivo studies, like swelling of 
astrocytes and oedema consistent with a metabolic 
encephalopathy and diffuse hypoxic neuronal damage 
[46]. 
It has to be noted that the results of the present in 
vitro study can be transferred to the clinical in vivo 
situation ot without restrictions, as rat primary ceils 
and cell lines have been used in the present study. 
Furthermore, in vivo pharmacokinetics is an essential 
factor which is excluded in vitro. This might be 
important in the case of the central nervous toxicity 
of cyclosporine and tacrolimus, Since cyclosporine 
cannot pass the blood-brain barrier [47], it has been 
hypothesized that its central nervous toxicity is mainly 
mediated by its constric6ve ffect on cerebral blood 
vessels. In contrast, it has been shown in cynomolgus 
monkeys that the concentrations of tacrolimus in the 
brain exceed those in blood several times [48]. Due to 
methodologic requirements, the concentrations which 
had to be used in this study were relatively high 
compared with those found in the blood with patients. 
However, it can be assumed that metabolic pathways 
that are not affected in vitro will not be influenced by 
the lower concentrations in vivo as well and that the 
mechanisms responsible for in vivo toxicity are among 
those characterized in the present in vitro study. 
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